Head-to-head evidence
bb21217 vs BCMA CAR-NK (Hrain)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA · full Multiple Myeloma pipeline
bb21217
Developed by 2seventy bio, Inc. (wholly-owned subsidiary of Bristol Myers Squibb)
NCT03274219 · Phase 1 · completed
There was no control group and no blinding: everyone in the study received bb21217, and the trial was designed to check safety rather than measure effectiveness. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
BCMA CAR-NK (Hrain)
Developed by Hrain Biotechnology Co., Ltd.
NCT05008536 · Phase 1 · status unknown
This was an open-label, single-arm study with no randomization, no blinding, and no comparator arm, in only 27 participants. Results have not been posted yet. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: bb21217's landscape · BCMA CAR-NK (Hrain)'s landscape